Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Furosemide

FDA-approved product (tablet, oral), marketed as Furoscix, Furoscix Readyflow (Autoinjector), Furosemide and 2 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Furosemide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Cirrhosis of liver
  • Congestive heart failure
  • Heart failure
  • Hypertension
  • Nephrotic syndrome
  • Pulmonary edema
  • Syndromic disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Sulfonamides, plain
FDA pharmacologic class
Loop Diuretic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA32.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli21.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae15.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Furosemide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Furosemide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Evaluating Adherence to Guideline-Directed Medical Therapy in Patients With Advanced Heart Failure

    NCT07560982 · start 2026-05-08

    Registered record
    Registry ID
    NCT07560982
    Conditions
    Heart Failure
    Interventions
    GDMT; Quality of life questionnaire
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2026-05-08
    Completion
    2036-07-01
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    InterventionGDMT; Quality of life questionnaire
    PhaseNot recorded
    Registry statusRecruiting

  • Study to Compare Bioavailability and Pharmacokinetics of a Novel Furosemide Regimen Administered Subcutaneously Versus the Same Dose (80 mg) Administered Intravenously in Healthy Volunteers

    NCT07269496 · start 2026-02-09

    Registered record
    Registry ID
    NCT07269496
    Conditions
    Healthy
    Interventions
    SQIN-Furosemide; Lasix ® Infusion
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2026-02-09
    Completion
    2026-03-09
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionSQIN-Furosemide; Lasix ® Infusion
    PhasePhase 1
    Registry statusCompleted

  • Efficacy and Safety of Early Initiation of Midodrine for Control and Prevention of Ascites and Its Related Complications in Acute-on-chronic Liver Failure.

    NCT07422948 · start 2026-02-05

    Registered record
    Registry ID
    NCT07422948
    Conditions
    Acute on Chronic Liver Failure
    Interventions
    Midodrine; Standard Medical Treatment
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-02-05
    Completion
    2027-08-30
    Enrolment
    113

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute on Chronic Liver Failure
    InterventionMidodrine; Standard Medical Treatment
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Simple Urine Composition-based Personalized Algorithm for Effective Congestion Relief in Decompensated Heart Failure

    NCT07099885 · start 2025-08-01

    Registered record
    Registry ID
    NCT07099885
    Conditions
    Acute Heart Failure (AHF); Congestion, Venous
    Interventions
    Standard of Care (SOC); Algorithhm-based decongestion
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-08-01
    Completion
    2027-01-31
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Heart Failure (AHF); Congestion, Venous
    InterventionStandard of Care (SOC); Algorithhm-based decongestion
    PhaseNot applicable
    Registry statusRecruiting

  • PuO2 in RenalGuard Pilot Study

    NCT06886191 · start 2025-03-17

    Registered record
    Registry ID
    NCT06886191
    Conditions
    Cardiac Surgery Subjects
    Interventions
    RenalGuard Therapy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2025-03-17
    Completion
    2026-12-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiac Surgery Subjects
    InterventionRenalGuard Therapy
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Furosemide-Digoxin vs. Polidocanol for Cutaneous Warts

    NCT07307131 · start 2024-09-01

    Registered record
    Registry ID
    NCT07307131
    Conditions
    Cutaneous Warts; Human Papilloma Virus (HPV)
    Interventions
    Intralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml); Intralesional polidocanol 2%
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2024-09-01
    Completion
    2025-09-30
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCutaneous Warts; Human Papilloma Virus (HPV)
    InterventionIntralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml); Intralesional polidocanol 2%
    PhasePhase 2
    Registry statusCompleted

  • Study to Examine the Effect of the Diuretic Furosemide on the Plasma Levels of Toxins and the Removal of Toxins from the Blood in Patients with Chronic Kidney Disease

    NCT06750575 · start 2024-06-10

    Registered record
    Registry ID
    NCT06750575
    Conditions
    Chronic Kidney Diseases; Renal Failure Chronic
    Interventions
    Invasive measurements
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2024-06-10
    Completion
    2025-07-01
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Diseases; Renal Failure Chronic
    InterventionInvasive measurements
    PhaseNot recorded
    Registry statusRecruiting

  • The Impact of Inhaled Furosemide and Perorally Administered Levodropropizine on Dyspnea in Patients With Respiratory Diseases

    NCT06252454 · start 2024-02-27

    Registered record
    Registry ID
    NCT06252454
    Conditions
    Dyspnea
    Interventions
    Furosemide 40 mg; Levodropropizine; Placebo - saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2024-02-27
    Completion
    2025-12
    Enrolment
    102

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDyspnea
    InterventionFurosemide 40 mg; Levodropropizine; Placebo - saline
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Vexus-guided Fluid Management in Patients With Septic Shock After the Resuscitation Phase

    NCT06227702 · start 2024-02-01

    Registered record
    Registry ID
    NCT06227702
    Conditions
    Critically Ill Patients; Septic Shock
    Interventions
    Fluid management according to Venous Excess Ultrasound (VExUS) Score
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2024-02-01
    Completion
    2026-02-28
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCritically Ill Patients; Septic Shock
    InterventionFluid management according to Venous Excess Ultrasound (VExUS) Score
    PhaseNot applicable
    Registry statusUnknown

  • Natriuresis-Guided Diuretic Therapy in Patients With Acute Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease

    NCT06203236 · start 2024-01

    Registered record
    Registry ID
    NCT06203236
    Conditions
    Acute Heart Failure; Chronic Kidney Diseases
    Interventions
    Furosemide 20 MG; diuretic therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2024-01
    Completion
    2025-11
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Heart Failure; Chronic Kidney Diseases
    InterventionFurosemide 20 MG; diuretic therapy
    PhasePhase 4
    Registry statusUnknown

  • Acute Effects of Furosemide on Hemodynamics and Pulmonary Congestion in Acute Decompensated Heart Failure.

    NCT06024889 · start 2023-09-01

    Registered record
    Registry ID
    NCT06024889
    Conditions
    Acute Heart Failure
    Interventions
    Furosemide Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2023-09-01
    Completion
    2024-02-09
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Heart Failure
    InterventionFurosemide Injection
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Diuretic Use in Hemodialysis Patients With Residual Renal Function

    NCT05915286 · start 2023-05-29

    Registered record
    Registry ID
    NCT05915286
    Conditions
    End Stage Renal Disease on Dialysis
    Interventions
    Furosemide; Chlorthalidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2023-05-29
    Completion
    2025-02-21
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEnd Stage Renal Disease on Dialysis
    InterventionFurosemide; Chlorthalidone
    PhasePhase 4
    Registry statusTerminated

  • A Study to Evaluate the Effects of D-1553 on PK of Midazolam, Caffeine, Rosuvastatin, Furosemide, Digoxin, and Itraconazole or Omeprazole on PK of D-1553

    NCT06105255 · start 2023-05-24

    Registered record
    Registry ID
    NCT06105255
    Conditions
    Healthy Male
    Interventions
    D-1553
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2023-05-24
    Completion
    2024-02-02
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Male
    InterventionD-1553
    PhasePhase 1
    Registry statusCompleted

  • Platform of Randomized Adaptive Clinical Trials in Critical Illness

    NCT05440851 · start 2023-04-30

    Registered record
    Registry ID
    NCT05440851
    Conditions
    Respiratory Insufficiency; Extracorporeal Membrane Oxygenation Complication; Mechanical Ventilation Pressure High
    Interventions
    Ultra-Protective Ventilation Facilitated by Extracorporeal Support; Lung-Protective Ventilation (LPV); Driving Pressure-Limited Ventilation (DPL); Lung- and Diaphragm-Protective Ventilation and Sedation (LDPVS); Early Cohort corticosteroid dose; Extended Cohort corticosteroid dose; Usual care without routine corticosteroids; Usual care without extending corticosteroids; Usual care with fludrocortisone; Usual care without fludrocortisone; Drug 4 mL:; Drug 40 mg:; PEEP-20; PEEP-AOP; PEEP-10; VV ECMO-facilitated strategy of earlier awakening, extubation and rehabilitation; Electrical impedance tomography (EIT); no treatment / intervention arm is involved; Usual care; Early Routine IMT; no treatment / intervention arm is involved.
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2023-04-30
    Completion
    2027-03-31
    Enrolment
    6,250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRespiratory Insufficiency; Extracorporeal Membrane Oxygenation Complication; Mechanical Ventilation Pressure High
    InterventionUltra-Protective Ventilation Facilitated by Extracorporeal Support; Lung-Protective Ventilation (LPV); Driving Pressure-Limited Ventilation (DPL); Lung- and Diaphragm-Protective Ventilation and Sedation (LDPVS) +17 more
    PhaseNot applicable
    Registry statusRecruiting

  • The Addition of Inhaled Furosemide to Standard Treatment of COPD Exacerbation

    NCT05769738 · start 2023-03

    Registered record
    Registry ID
    NCT05769738
    Conditions
    Chronic Obstructive Pulmonary Disease Exacerbation; COPD Exacerbation
    Interventions
    Furosemide; Normal saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2023-03
    Completion
    2024-12
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Obstructive Pulmonary Disease Exacerbation; COPD Exacerbation
    InterventionFurosemide; Normal saline
    PhasePhase 3
    Registry statusUnknown